Finland's ICEYE raised €1 billion this week at a valuation above €10 billion, the largest private funding round in European spacetech to date. The signal is not the size of the round. ICEYE crossed €250M in annual revenue and €100M in EBITDA in 2025, with seven European governments paying for sovereign access to its SAR satellite constellation. European intelligence infrastructure now has a profitable, scaled operator.
Startups & Funding
ICEYE closes €450M primary round as its constellation becomes critical government infrastructure
Finland's ICEYE raised €450 million in a primary Series F led by General Atlantic on June 9, with Finnish institutional investors Solidium, Tesi, Varma, and Ilmarinen, Nokia, Qatar Investment Authority, TCV, and Lifeline Ventures also participating. Including a secondary placement, the total Series F exceeded €1 billion.
The commercial position behind that number: ICEYE crossed €250M in revenue and €100M in EBITDA in 2025, with a contracted backlog of over €1.5B. Seven European governments have procured sovereign satellite systems from the company. Production scales from 50 satellites per year now to a target of 100 annually by 2028.
That trajectory is what distinguishes the round from other large European raises. ICEYE is not pre-revenue or pre-product. It is a profitable business doubling its production rate.
(Bloomberg / EU-Startups)
NewOrbit raises $18.5M to build the first commercial VLEO manufacturing facility
UK-based NewOrbit closed an oversubscribed $18.5M Series A on June 8, led by Voyager Ventures with Atlantic VC, Lifeline Ventures, and Illusian. The company is building satellites for very low Earth orbit (200–300km altitude), a band that enables higher-resolution imagery and lower-latency communications than conventional constellations but has never had commercial manufacturing infrastructure.
The round funds a production complex planned for 2027, with the first commercial satellite targeting launch in 2028. David Kirk, Nvidia's former chief scientist, joined as an angel investor. His interest signals that the sensor and compute integration required for VLEO is drawing attention from beyond aerospace. Reading-based, founded 2021.
(SpaceNews / EU-Startups)
Innovafeed secures €51M as insect protein hits the industrialisation phase
Paris-based Innovafeed closed €51 million on June 5, backed by existing investors Creadev, QIA, Temasek, and FFC. The Nesle production facility in northern France is now fully operational: over three years, the company has produced more than 15,000 tonnes of black soldier fly protein and oil, with volumes up tenfold and production costs down sevenfold.
The company is cutting R&D headcount and redirecting resources toward commercial growth, targeting aquaculture and pet food markets with its Hilucia ingredient range. The restructuring is a deliberate signal. The science is settled, the manufacturing works, and the variable now is market penetration.
Rem3dy Health raises €16M to take 3D-printed personalised nutrition global
Birmingham-based Rem3dy Health closed €16 million on June 9, led by Future Planet Capital with strategic investors Suntory, Estrella Galicia, Apollo Hospitals, and UPSA. The round values the company at £84 million. Rem3dy's Nourished brand uses AI-driven health questionnaires and 3D printing to produce bespoke gummy supplement stacks, manufactured at its UK facility.
The investor roster is a map of the expansion plan: the US, MENA, and India. The product differentiation sits in the manufacturing process. Each stack is physically assembled to a customer's nutritional profile, not a standard formulation with personalised packaging.
Products & Technology
n8n commits to 200 UK staff by 2029 at London Tech Week
Berlin-based n8n announced a commitment to 200 UK-based employees by 2029 at London Tech Week on June 9. The company operates an AI orchestration platform for enterprise workflows, with 1.8 million monthly active developers and more than 35% of the Fortune 500 among its customers, including Vodafone and UK government ministries.
SAP invested in n8n in May, doubling the company's valuation to $5.2 billion. The UK commitment goes beyond a headcount target. n8n is positioning Britain as a second home market for enterprise sales and engineering, not an export territory. For a German AI company, that is a meaningful structural shift.
(n8n Blog)
Euro-Office 1.0 ships — now comes the procurement test
Euro-Office 1.0 launched on June 9, the browser-based productivity suite built by a consortium including IONOS, Nextcloud, Eurostack, XWiki, and OpenProject. The suite covers document editing, spreadsheets, presentations, and PDF editing, with full support for DOCX, XLSX, PPTX, and ODF formats.
The technology is not the constraint. The suite shipped on time and covers the core feature set. The question flagged when the launch was announced — whether European public administrations will integrate it into live procurement decisions — is now the only question that matters. Watch for: formal inclusion in German federal IT framework agreements, any Commission signals on internal adoption, and contribution volume from institutional rather than individual developers in the months ahead.
Climate & Energy
Vienna wins EUSEW Local Energy Award for its gas phaseout programme
The City of Vienna's "100 Projects Phasing Out Gas" initiative won the Local Energy Action award at the 2026 European Sustainable Energy Week ceremony in Brussels on June 9. Led by UIV Urban Innovation Vienna, the programme works toward Vienna's target of 100% renewable energy by 2040 through coordinated heat pump rollouts, building retrofits, and district heating expansion across the city.
The award matters for what it recognises: not a technology company or a prototype, but a city government running a gas phaseout at municipal scale. Vienna's governance structure and pre-existing district heating network make direct replication difficult elsewhere. The programme's real value is as a reference for what integrated city-level energy transition looks like when it runs.
Research & Deep Tech
Cambridge and DIOSynVax report first human trial of a fully AI-designed vaccine
Researchers at the University of Cambridge and DIOSynVax reported on June 5 that the first human clinical trial of a vaccine designed entirely by machine learning found the candidate safe and immunogenic. The pan-Sarbecovirus vaccine pEVAC-PS uses AI-specified super-antigens, protein structures with no natural equivalent, to generate immune responses across SARS-CoV-2, SARS-CoV-1, and related bat coronaviruses.
The phase I trial ran in 39 healthy volunteers. The result establishes that AI-designed antigen structures can be synthesised, manufactured, and tested in humans without safety signals. The next question is whether the platform generalises: can the same approach compress timelines for novel pandemic pathogens? Phase II has not been announced.
CERN opens public debate on the Future Circular Collider
CERN launched its public consultation on the Future Circular Collider (FCC) project across France and Switzerland on June 4, running through October 2026. The FCC-ee proposal is a 91-kilometre electron-positron collider designed as the LHC's successor, with a build-versus-no-build decision by the CERN Council expected around 2028.
The French consultation is led by the Commission Nationale du Débat Public, the mandatory public debate process for major infrastructure decisions. If approved, construction could begin in the early 2030s, with initial operation planned for the mid-2040s. What is being decided is not only the physics agenda but whether Europe will commit to the largest scientific infrastructure project in its history.
(CERN)
One to Watch
DIOSynVax: testing whether AI antigen design scales to new targets
Cambridge spin-out DIOSynVax built pEVAC-PS by using machine learning to specify protein structures that don't exist in nature, then synthesising them for testing. That approach sidesteps the evolutionary constraints that shape conventional vaccine design. The phase I result shows the method works once.
The test now is repeatability: can the platform produce validated candidates for novel targets without the same multi-year development cycle? Watch for the number of candidates entering development in 2026 and whether any are on accelerated timelines for emerging pathogens. The phase I result is proof that the approach can work. What the pipeline does next will determine whether it is a platform.